Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3796393 | 1.00 | ADORA2B (0.49) | ADORA2BADORA3ADORA1TYMPADORA2A | |
| SCHEMBL13057654 | 0.91 | TYMP (0.51) | ADORA2BADORA3ADORA1TYMPADORA2A | |
| SCHEMBL18496453 | 0.91 | TYMP (0.51) | ADORA2BADORA3ADORA1TYMPADORA2A | |
| SCHEMBL3796369 | 0.89 | ADORA2B (0.44) | ADORA2BADORA3ADORA1TYMPADORA2A | |
| SCHEMBL19666774 | 0.88 | TYMP (0.56) | ADORA2BADORA3ADORA1TYMP | |
| SCHEMBL29397739 | 0.88 | TYMP (0.65) | ADORA2BADORA3ADORA1TYMP | |
| SCHEMBL13020571 | 0.86 | ADORA2B (0.42) | ADORA2BADORA3ADORA1TYMPADORA2A | |
| SCHEMBL1068389 | 0.83 | TYMP (0.55) | ADORA1TYMP | |
| SCHEMBL1068391 | 0.83 | TYMP (0.55) | ADORA1TYMP | |
| SCHEMBL23953082 | 0.83 | P2RY1 (0.46) | ADORA2BADORA3ADORA1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011005595-A2 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | ADORA2B 1054/4885ADORA3 1626/4885ADORA1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.